Sharma, Vivek http://orcid.org/0000-0003-4871-2114
Koprivnikar, Jamie
Drago, Kristen
Savage, Jessica
Bachelor, Allison
Funding for this research was provided by:
Apellis Pharmaceuticals (-)
Swedish Orphan Biovitrum (-)
Article History
Received: 6 July 2023
Accepted: 16 August 2023
First Online: 14 September 2023
Declarations
:
: KD, JS, and AB are employees of Apellis Pharmaceuticals, Inc and hold stock options. VS is on the speaker’s bureau for Alexion, Sanofi, and Novo Nordisk. JK: is on the advisory board/consultant for Apellis, Novartis and Alexion, and is on the speaker's bureau for Alexion, Apellis, Amgen, Jazz, CTI, BMS, and AbbVie.
: The studies included in this analysis were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki [CitationRef removed, CitationRef removed]. The study protocols were approved by relevant institutional review boards or ethics committees at each site, and all patients provided written informed consent. PEGASUS and the 307 OLE were registered on ClinicalTrials.gov (NCT03500549 and NCT03531255, respectively).